Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00 per share Read the full story
Tag Archive | "Valeant"
Valeant acquires Salix Pharma for $14.5 billion
Posted on 23 February 2015
Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix Read the full story
M&A news: who will win the bidding race?
Posted on 16 February 2015
M&A news: The Canadian pharma company Valeant Pharmaceuticals is rumoured to be raising money to make a bid for specialty drugmaker Salix Pharmaceuticals, according to Bloomberg, which cites people familiar with the matter.
Valeant Pharmaceuticals raises $1 billion in private financing
Posted on 15 January 2015
Big pharma, Valeant Pharmaceuticals International, has completed the private placement financing of senior unsecured notes due 2023, for gross proceeds of USD1 billion. Read the full story
Asset purchase agreement for dermatology product portfolio
Posted on 26 August 2014
Valeant Canada has completed the acquisition of Valeo Pharma's dermatology product portfolio and several specialty products. Read the full story
Valeant extends the acquisition of Allergan
Posted on 19 August 2014
Valeant Pharmaceuticals has extended the acquisition period for Allergan. Read the full story
ECR Pharma is acquired by Valeant
Posted on 23 June 2014
Akorn has sold its subsidiary, ECR Pharmaceuticals, to Valeant Pharmaceuticals for $41 million in cash and assumption of certain liabilities. Read the full story
Valeant
Posted on 07 June 2014
Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada Read the full story
Valeant plans for a hostile takeover of Allergan
Posted on 03 June 2014
Valeant Pharmaceuticals and Pershing Square plan to approach the shareholders of Allergan for a hostile takeover. Read the full story
Valeant sells its dermatology products for $1.4 billion
Posted on 29 May 2014
Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Read the full story
